Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 27;41(13):2234–2242. doi: 10.1016/j.vaccine.2023.02.068

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Anti-RBD IgG titers and neutralizing titers at 2 and 5 months after two doses and the third dose of mRNA vaccine in participants with or without BTI. (A) SARS-CoV-2 RBD IgG antibody titers, (B) Neutralizing titers against SARS-CoV-2pv of SARS-CoV-2 naïve participants. (C) SARS-CoV-2 RBD IgG antibody titers, (D) Neutralizing titers of participants with BTI during BA.1 epidemic period (January to March 2022). (E) SARS-CoV-2 RBD IgG antibody titers, (F) Neutralizing titers of participants with BTI during BA.5 epidemic period (June to September 2022). 14 participants were infected from January to March 2022 (during the Omicron BA.1 epidemic period); and 36 participants were infected from June to September 2022 (during the Omicron BA.5 epidemic period). ^***, p < 0.001; ^**, p < 0.01; *, p < 0.05; NS, not significant. Abbreviations: RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; V2, 2nd dose of vaccine; V2 + 2 M, 2 months after the 2nd dose of vaccine; V2 + 5 M, 5 months after the 2nd dose of vaccine; V3, 3rd dose of vaccine; V3 + 2 M, 2 months after the 3rd dose of vaccine; V3 + 5 M, 5 months after the 3rd dose of vaccine; BTI, breakthrough infection.